Company/Division name | Ferring Pharmaceuticals |
Type of work | Manufacturing |
If manufacturing, is the company an OEM? | Yes |
Reshoring category: | Transplant |
Total number of jobs (added or to be added): | 375 |
What product(s) and/or service(s) were outsourced domestically? | Manufacturing |
Year reshoring announced: | 2014 |
Year reshoring implemented or to be implemented: | 2016 |
Offshore, work was done: | In-house |
Domestically, the work will be done: | In-house |
Capital investment ($): | 135 |
$/year of sales of reshored product or service: | 200 |
Country(ies) from which reshored: | Swaziland |
City reshored to: | Parsippany |
State(s) reshored to: | NJ |
If relevant, work nearshored to: | - |
Industry(ies): | Chemicals |
Product(s) reshored | Pharmaceuticals |
What domestic positive factors made reshoring more attractive? | Eco-system synergies, Higher productivity, Manufacturing/engineering joint innovation (R&D) |